ABSTRACT
In Brazil, the treatment of hepatitis C virus (HCV) infection is funded by the national public health system (SUS). To evaluate treatment results in the state of Mato Grosso, central Brazil, we have consulted the files of the office of the State Department of Health responsible for supplying such medications. We obtained information on 232 treatments of 201 patients who underwent treatment in or prior to 2008. The study was conducted by reviewing medical records, making telephone calls and interviewing the assistant physicians. Thirty-nine patients (19.4 percent) had cirrhosis and HCV genotype 1 predominated (64.3 percent). Excluding patients with comorbidities or treatment without ribavirin we analysed 175 treatments (sustained virologic response occurred in 32.6 percent of cases). Twenty-six of these 175 were retreatments and the sustained virological response (SVR) rate among them was 30.8 percent; the SVR rate was 32.9 percent among those receiving treatment for the first time. The SVR rate of genotype 1 patients was 27.8 percent, whereas it was 37.5 percent in non-1 genotype patients. The adjusted multivariate analysis showed association of SVR with the absence of cirrhosis [odds ratio (OR): 7.7; confidence interval (CI) 95 percent: 2.5, 33.3], the use of pegylated interferon (OR: 5.8; CI 95 percent: 1.5, 21.4), non-1 genotype (OR: 5.3; CI 95 percent: 1.7, 16.7) and uninterrupted treatment (OR: 9.0; CI 95 percent: 3.3, 45.4). The SVR rates were similar to those found in other Brazilian studies about HCV, but lower than those found in national and international clinical trials. These data suggest that the treatments of chronic hepatitis C that are made available by SUS does not, under normal conditions, work as well as the original controlled studies indicated.